PARTICULARS TO APPEAR ON THE OUTER PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Combiclav Suspension for Injection

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Combiclav Injection is an off-white suspension for injection containing amoxicillin 14.0 mg/ml as amoxicillin trihydrate and clavulanic acid 35 mg/ml as potassium clavulanate in an oily base.

Also contains Butylated Hydroxyanisole 0.08 mg/ml and Butylated Hydroxytoluene 0.08 mg/ml.

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

50 ml /100 ml multidose vial.

5. TARGET SPECIES

Cattle

6. INDICATION(S)

Combiclav Injection has a broad-spectrum of bactericidal activity against the bacteria commonly found in cattle.

(a) *In vitro* Combiclav Injection is active against a wide range of clinically important bacteria including:

Gram-positive: *Staphylococci* (including beta-lactamase producing strains), *Streptococci, Corynebacteria, Clostridia, Bacillus anthracis*, *Actinomyces bovis*.

Gram-negative: *Escherichia coli* (including beta-lactamase producing strains), *Salmonella* spp, (including beta-lactamase producing strains), *Campylobacter* spp, *Klebsiella* spp, *Proteus* spp, *Pasteurella* spp, *Fusobacterium necrophorum*, *Bacteroides* spp, (including beta-lactamase producing strains), *Haemophilus* spp, *Moraxella* spp and *Actinobacillus lignieresi.*

(b) Combiclav Injection is effective against bacteria which cause a wide range of diseases:

In cattle these include:
Respiratory infections
Soft tissue infections (e.g. joint/navel ill, abscesses etc.)
Metritis
Mastitis

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

By intramuscular injection at a dosage rate of 8.75 mg/kg bodyweight (1 ml per 20 kg bodyweight) daily for 3-5 days.

Shake the vial well before use. Use a completely dry sterile needle and syringe. Swab the septum before removing each dose. After injection, massage the injection site.

The suspension is not suitable for intravenous or intrathecal administration.

Combined Therapy for the treatment of bovine mastitis. In the situation where systemic treatment as well as intramammary treatment is necessary, Combiclav Injection can be administered in combination with Combiclav Lactating Cow Intramammary Suspension using the following minimum treatment regime:

Combiclav Injection	**Combiclav LC Intramammary**
8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight. 24 hours ↓ 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight. 24 hours ↓ 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight. Where necessary Combiclav Injection may be administered for an additional two days for a total of 5 daily injections.	One syringe gently infused into the teat of the infected quarter 12 hours ↓ One syringe gently infused into the teat of the infected quarter 12 hours ↓ One syringe gently infused into the teat of the infected quarter

To ensure the correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.

8. WITHDRAWAL PERIOD

Meat and offal: 42 days.
Milk: 60 hours

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Official and local antimicrobial policies should be taken into account when the product is used.
Avoid use of the product in herds where no β-lactamase producing *Staphylococci* strains have been isolated. Veterinarians should strive to use narrow spectrum antibiotics if possible.
Inappropriate use of the product may increase the prevalence of bacteria resistant to ß-lactam antibiotics and may decrease the effectiveness of treatment with ß-lactam antibiotics, due to the potential for cross-resistance.

The product should not be administered to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in its use in other very small herbivores.

Use of the product may occasionally result in pain on injection and/or local tissue reaction.

User Warnings: Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Care should be taken to avoid accidental self-injection.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
Wash hands after use.

Clavulanic acid is moisture sensitive. It is very important, therefore, that a completely dry syringe is used when extracting suspension for injection to avoid contaminating the remaining contents of the vial with water.

Contamination will result in distinct beads of dark, brown discolouration corresponding to the introduced water droplets. Material affected in this way should not be used as it may have significantly reduced potency.

Shake the vial before use. This product does not contain an antimicrobial preservative. Swab the septum before removing each dose. Use a dry sterile needle and syringe.

Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanic acid in Combiclav Injection counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the bacteria sensitive to amoxicillin's rapid bactericidal effect, at concentrations readily attainable in the body.

10. EXPIRY DATE

Exp.:

11. SPECIAL STORAGE CONDITIONS

Do not store above 25ºC.
Keep container in outer carton.

Once a vial has been broached the contents should be used within 28 days. Discard unused material.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of waste material in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

FOR ANIMAL TREATMENT ONLY

POM-V

To be supplied only on veterinary prescription

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reachof children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited
Station Works
Camlough Road
Newry
Co. Down
BT35 6JP
Northern Ireland

Manufactured by:
Norbrook Laboratories Limited,
Station Works,
Newry,
Co. Down, BT35 6JP

Distributed by:
Norbrook Laboratories Limited
Carnbane Industrial Estate
Newry
Co. Down
BT35 6QQ
Northern Ireland

16. MARKETING AUTHORISATION NUMBER

Vm: 02000/4238
ManA 2000

17. MANUFACTURER'S BATCH NUMBER

B.N.:
DOM:

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Combiclav Suspension for Injection

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

This product contains amoxicillin 140 mg/ml as amoxicillin trihydrate and clavulanic acid 35 mg/ml as potassium clavulanate in an oily base.

Also contains Butylated Hydroxyanisole 0.08 mg/ml and Butylated Hydroxytoluene 0.08 mg/ml

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

100ml

5. TARGET SPECIES

Cattle

6. INDICATION(S)

Combiclav Injection has a broad spectrum of bactericidal activity against the bacteria commonly found in cattle.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cattle: By intramuscular injection at a dosage rate of 8.75 mg/kg bodyweight (equivalent to 1 ml per 20 kg bodyweight) daily for 3 to 5 days. Shake the vial well before use. Use a completely dry needle and syringe. Swab the septum before removing each dose. After injection massage the injection site.

8. WITHDRAWAL PERIOD

Meat and offal: 42 days.
Milk: 60 hours.

9. SPECIAL WARNING(S), IF NECESSARY

The product should not be administered to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in its use in other very small herbivores.
Penicillins and cephalosporins may occasionally cause severe allergic reactions. See package leaflet for user warnings.
Further Information: Refer to Package leaflet.

10. EXPIRY DATE

Exp.: dd/mm/yy

11. SPECIAL STORAGE CONDITIONS

Do not store above 25ºC.

Keep container in outer carton.

Once a vial has been broached the contents should be used within 28 days.
Discard Date:…….

Discard unused material.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of waste material in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

FOR ANIMAL TREATMENT ONLY.

POM-V

To be supplied only on veterinary prescription

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited
Station Works
Camlough Road
Newry
Co. Down
BT35 6JP
Northern Ireland

Manufacturer:
Norbrook Laboratories Limited,
Station Works,
Newry,
Co. Down, BT35 6JP

Distributed by:
Norbrook Laboratories Limited
Carnbane Industrial Estate
Newry
Co. Down
BT35 6QQ
Northern Ireland

16. MARKETING AUTHORISATION NUMBER

Vm: 02000/4238

17. MANUFACTURER'S BATCH NUMBER

B.N.:
DOM:

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Combiclav Suspension for Injection

2. QUANTITY OF THE ACTIVE SUBSTANCES

This product contains amoxicillin 140 mg/ml as amoxicillin trihydrate and clavulanic acid 35 mg/ml as potassium clavulanate in an oily base.

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

50 ml

4. ROUTE(S) OF ADMINISTRATION

Cattle: By intramuscular injection at a dosage rate of 8.75 mg/kg bodyweight (equivalent to 1 ml per 20 kg bodyweight) daily for 3 to 5 days. Shake the vial well before use. Use a completely dry needle and syringe. Swab the septum before removing each dose. After injection massage the injection site.

5. WITHDRAWAL PERIOD

Meat and offal: 42 days.
Milk: 60 hours.

6. BATCH NUMBER

Lot

7. EXPIRY DATE

Exp.: dd/mm/yy

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

FOR ANIMAL TREATMENT ONLY.

9. MARKETING AUTHORITSATION HOLDER

Norbrook Laboratories Limited

PACKAGE LEAFLET FOR:

Combiclav Suspension for Injection

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Norbrook Laboratories Limited
Station Works
Camlough Road
Newry
Co. Down
BT35 6JP
Northern Ireland

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Combiclav Suspension for Injection

3. STATEMENT OF THE ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS

Combiclav Injection is an off-white suspension for injection containing amoxicillin 140 mg/ml as amoxicillin trihydrate and clavulanic acid 35 mg/ml as potassium clavulanate in an oily base. Also contains Butylated Hydroxyanisole 0.08 mg/ml and Butylated Hydroxytoluene 0.08 mg/ml.

4. INDICATION(S)

Combiclav Injection has a broad spectrum of bactericidal activity against the bacteria commonly found in cattle.

(a) *In vitro* Combiclav Injection is active against a wide range of clinically important bacteria including:

Gram-positive: Staphylococci (including beta-lactamase producing strains), Streptococci, Corynebacteria, Clostridia, *Bacillus anthracis*, *Actinomyces bovis*.

Gram-negative: *Escherichia coli* (including beta-lactamase producing strains), *Salmonella* spp, (including beta-lactamase producing strains), *Campylobacte*r spp, *Klebsiella* spp, *Proteus* spp, *Pasteurella* spp, *Fusobacterium necrophorum*, *Bacteroides* (including beta-lactamase producing strains), *Haemophilus* spp, *Moraxella* spp and *Actinobacillus lignieresi.*

(b) Combiclav Injection is effective against bacteria which cause a wide range of diseases:

In cattle these include:
Respiratory infections
Soft tissue infections (e.g. joint/navel ill, abscesses etc.)
Metritis
Mastitis

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information.

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

The product should not be administered to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in its use in other very small herbivores.

Use of the product may occasionally result in pain on injection and/or local tissue reaction.

6. ADVERSE REACTIONS

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Cattle

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

By intramuscular injection at a dosage rate of 8.75 mg/kg bodyweight (1 ml per 20 kg bodyweight) daily for 3-5 days.

Shake the vial well before use. Use a completely dry sterile needle and syringe. Swab the septum before removing each dose. After injection, massage the injection site.

The suspension is not suitable for intravenous or intrathecal administration.

Combined therapy for the treatment of bovine mastitis: In the situation where systemic treatment as well as intramammary treatment is necessary, Combiclav Injection can be administered in combination with Combiclav Lactating Cow Intramammary Suspension using the following minimum treatment regime:

Combiclav Injection	**Combiclav LC Intramammary**
8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight. 24 hours ↓ 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight. ↓	One syringe gently infused into the teat of the infected quarter 12 hours ↓ One syringe gently infused into the teat of the infected quarter 12 hours ↓

24 hours 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight. Where necessary Combiclav Injection may be administered for an additional two days for a total of 5 daily injections.	One syringe gently infused into the teat of the infected quarter

To ensure the correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.

9. ADVICE ON CORRECT ADMINISTRATION

Shake the vial well before use. Use a completely dry sterile needle and syringe. Swab the septum before removing each dose. After injection, massage the injection site.

10. WITHDRAWAL PERIOD(S)

Meat and offal: 42 days.
Milk: 60 hours

11. SPECIAL STORAGE PRECAUTIONS

Do not store above 25ºC.
Once a vial has been broached the contents should be used within 28 days.
Keep out of the reach and sight of children.
Discard unused material.
Keep container in outer carton.

When the container is broached (opened) for the first time, using the in-use shelf-life which is specified on this package leaflet, the date on which any product remaining in the carton should be discarded should be worked out. This discard date should be written in the space provided.

12. SPECIAL WARNING(S)

Special precautions for use in animals:
Official and local antimicrobial policies should be taken into account when the product is used.
Avoid use of the product in herds where no β-lactamase producing *Staphylococci* strains have been isolated. Veterinarians should strive to use narrow spectrum antibiotics if possible.
Inappropriate use of the product may increase the prevalence of bacteria resistant to ß-lactam antibiotics and may decrease the effectiveness of treatment with ß-lactam antibiotics, due to the potential for cross-resistance.
Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanic acid in Combiclav Injection counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the bacteria sensitive to amoxicillin's rapid bactericidal effect, at concentrations readily attainable in the body.

Clavulanic acid is moisture sensitive. It is very important, therefore, that a completely dry syringe is used when extracting suspension for injection to avoid contaminating the remaining contents of the vial with drops of water.

Contamination will result in distinct beads of dark, brown discoloration corresponding to the introduced water droplets. Material affected in this way should not be used as it may have significantly reduced potency.

Shake the vial before use. This product does not contain an antimicrobial preservative. Swab the septum before removing each dose. Use a dry, sterile needle and syringe.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Care should be taken to avoid accidental self-injection.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
Wash hands after use.

Incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Medicines should not be disposed of via wastewater. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

October 2022

15. OTHER INFORMATION

50 ml and 100 ml multidose vials.
Not all pack sizes may be marketed.

FOR ANIMAL TREATMENT ONLY.

POM-V

To be supplied only on veterinary prescription.

MARKETING AUTHORISATION NUMBER
Vm 02000/4238

Distributed by:
Norbrook Laboratories Limited
Carnbane Industrial Estate
Newry
Co. Down
BT35 6QQ
Northern Ireland



Approved: 28 October 2022